Stockreport

Nuvectis Pharma, Inc. Reports 2024 Financial Results and Business Highlights [Yahoo! Finance]

Nuvectis Pharma, Inc.  (NVCT) 
PDF FDA. Updated Phase 1b results anticipated in Q2 2025 NXP900 Phase 1a dose escalation study continues to enroll, preparation for the start of the Phase 1b program is un [Read more]